Compare LGIH & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | GERN |
|---|---|---|
| Founded | 2003 | 1990 |
| Country | United States | United States |
| Employees | N/A | 229 |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 2013 | N/A |
| Metric | LGIH | GERN |
|---|---|---|
| Price | $40.56 | $1.29 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 5 | 3 |
| Target Price | ★ $75.90 | $2.17 |
| AVG Volume (30 Days) | 415.7K | ★ 15.7M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $1,705,504,000.00 | N/A |
| Revenue This Year | $2.32 | $26.91 |
| Revenue Next Year | $17.94 | $43.75 |
| P/E Ratio | $487.56 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.55 | $1.04 |
| 52 Week High | $69.42 | $2.01 |
| Indicator | LGIH | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 39.15 | 32.86 |
| Support Level | $34.71 | $1.24 |
| Resistance Level | $41.50 | $1.49 |
| Average True Range (ATR) | 2.33 | 0.09 |
| MACD | -0.64 | -0.02 |
| Stochastic Oscillator | 1.03 | 0.00 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.